SCR7 pyrazine

SCR7 pyrazine is a DNA ligase IV inhibitor that blocks nonhomologous end-joining (NHEJ) in a ligase IV-dependent manner. SCR7 pyrazine increases the efficiency of Cas9-mediated homology-directed repair (HDR) . SCR7 pyrazine induces cell apoptosis and has anticancer activity[1][2].

Product Specifications

CAS Number

[14892-97-8]

UNSPSC

12352005

Hazard Statement

H302

Target

Apoptosis; CRISPR/Cas9; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/scr7-pyrazine.html

Purity

99.88

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1NC(NC2=NC(C3=CC=CC=C3)=C(C4=CC=CC=C4)N=C12)=S

Molecular Formula

C18H12N4OS

Molecular Weight

332.38

Precautions

H302

References & Citations

[1]Srivastava M, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. 2012 Dec 21;151 (7) :1474-87.|[2]Lin C, et al. Increasing the Efficiency of CRISPR/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells. Sci Rep. 2016 Oct 7;6:34531.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Int J Mol Sci. 2022 Jul 7;23 (14) :7518.|Int J Mol Sci. 2025 May 3;26 (9) :4361.|Nat Commun. 2025 Jul 15;16 (1) :6502.|Sci Adv. 2025 Jul 11;11 (28) :eadw1720.|Trends Biotechnol. 2025 Aug 30:S0167-7799 (25) 00314-2.|Trends Biotechnol. 2025 Jul;43 (7) :1743-1764.|University of Georgia. 2025.|Virology. 2025 May:606:110504.|BMC Biotechnol. 2021 Jul 27;21 (1) :45.|Cell Death Discov. 2025 Aug 23;11 (1) :402.|EMBO Rep. 2019 Mar;20 (3) :e46821.|J Genet Genomics. 2021 Feb 20;48 (2) :134-146.|J Immunol. 2020 Apr 1;204 (7) :1904-1918.|J Immunother Cancer. 2022 Jan;10 (1) :e003809.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Mol Ther Nucleic Acids. 2024 Jul 17;35 (3) :102274.|Onco Targets Ther. 2018 Aug 17:11:4945-4953.|Sens Actuators B Chem. 19 February 2022, 131598.|Stem Cell Res Ther. 2024 Dec 2;15 (1) :458.|Viruses. 2023 Nov 14;15 (11) :2256.